# DESCRIPTION

## FIELD

- define field of invention

## BACKGROUND

- motivate liver cancer treatment
- describe glypican-3 protein
- discuss heparan sulfate proteoglycans

## SUMMARY

- introduce human monoclonal antibodies
- describe antibody compositions and uses
- outline methods of diagnosis and treatment

## DETAILED DESCRIPTION

### I. Abbreviations

- define abbreviations

### II. Terms and Methods

- define technical terms
- explain antibody structure
- describe antibody types
- define monoclonal antibody
- explain chimeric antibody
- define human antibody
- explain humanized antibody
- define binding affinity
- describe chemotherapeutic agents
- explain conservative variants
- define complementarity determining region
- explain contacting
- describe cytotoxicity
- define degenerate variant
- explain diagnostic
- describe effector molecule
- define epitope
- define terms related to cancer
- define terms related to cells and biological components
- define terms related to antibodies and immunoconjugates
- define terms related to linkers and conjugation
- define terms related to mammals and subjects
- define terms related to neoplasia and tumors
- define terms related to nucleic acids and gene expression
- define terms related to pharmaceutical agents and carriers
- define terms related to preventing, treating, or ameliorating diseases
- define terms related to promoters and gene regulation
- define terms related to purification and protein preparation
- define terms related to recombinant nucleic acids and toxins
- define terms related to samples and biological specimens
- define terms related to sequence identity and homology
- define terms related to squamous cell carcinoma
- define terms related to subjects and living organisms
- define terms related to therapeutically effective amounts
- define terms related to toxins and cytotoxicity
- define terms related to vectors and gene delivery
- provide general explanations and disclaimers
- provide information on incorporated references
- provide information on controlling specifications

### III. Introduction

- introduce monoclonal antibodies for GPC3 and HS chains on GPC3

### IV. Human Monoclonal Antibodies that Bind GPC3 or HS Chains on GPC3

- describe human monoclonal antibodies that bind GPC3 or HS chains on GPC3
- introduce HN3 - single domain monoclonal antibody specific for GPC3
- provide DNA and protein sequences for HN3
- describe CDRs of HN3
- describe binding affinity of HN3
- introduce HS20 - monoclonal antibody specific for HS chains on GPC3
- provide DNA and protein sequences for HS20
- describe CDRs of HS20
- describe binding affinity of HS20
- describe modified version of HS20 (HS20 Mt)
- provide nucleotide and amino acid sequences of VL domain of HS20 Mt
- describe isolated human monoclonal antibodies that bind HS chains on GPC3
- describe compositions comprising therapeutically effective amount of disclosed antibodies
- introduce immunoconjugates comprising disclosed antibodies and effector molecule
- describe isolated nucleic acid molecules encoding disclosed human monoclonal antibodies
- describe expression vectors comprising isolated nucleic acid molecules
- describe isolated host cells comprising nucleic acid molecules or vectors

### V. Immunoconjugates

- define immunoconjugates
- describe therapeutic agents
- motivate choice of therapeutic agent
- describe construction of clones
- describe attachment of effector molecules
- describe linkers
- describe cleavable linkages
- describe derivatization of antibodies
- describe labeling of antibodies
- describe cross-linking of antibodies
- describe toxins and immunotoxins
- describe PE variants
- describe targeting of diagnostic or therapeutic compounds

### VI. Compositions and Methods of Use

- provide compositions with antibodies that bind GPC3 or HS on GPC3
- formulate antibodies for administration
- describe pharmaceutical compositions
- detail solution preparation
- list auxiliary substances
- provide dosage ranges
- describe lyophilized form
- outline infusion methods
- introduce controlled release formulations
- describe particulate systems
- detail microspheres and microcapsules
- discuss nanoparticles
- provide polymer examples
- introduce ion-controlled release
- describe liposomes
- list additional controlled delivery systems
- outline therapeutic methods
- describe cancer treatment
- detail administration with other anti-cancer agents
- list anti-cancer agents
- introduce immunomodulators
- describe surgical and radiotherapy treatments
- outline methods for diagnosis and detection

## EXAMPLES

### Example 1

- introduce HN3—a human single-domain monoclonal antibody
- describe cell lines and cell culture methods
- outline phage display and panning method
- express and purify HN3-hFc
- perform flow cytometry
- conduct ELISA
- perform WST-8 cell growth assay
- isolate an anti-GPC3 single-domain human mAb
- analyze binding properties of HN3 on cancer cells
- measure binding affinities of HN3 to GPC3 protein and cells
- perform epitope mapping
- investigate effects of HN3 on HCC cell proliferation
- analyze cell cycle and apoptosis
- study hippo/Yap, TGFβ, and Wnt signaling pathways
- discuss implications of HN3 as a therapeutic agent for liver cancer

### Example 2

- introduce HS20 antibody
- describe cell lines
- generate GPC3-expressing cell line
- produce recombinant GPC3 proteins
- select phage antibodies
- characterize phage binding
- construct HS20 human IgG
- analyze HS20 binding by Western blot and flow cytometry
- perform immunohistochemistry
- introduce tissue preparation
- describe immunostaining procedure
- assess specificity of immunostaining
- evaluate cell migration by wound healing scratch assay
- perform statistical analysis
- isolate HS20 Fv
- characterize binding properties of HS20
- analyze binding of HS20 on cancer cells
- determine binding site of HS20 on GPC3
- evaluate HS20 inhibition of HCC cell migration
- examine interaction of GPC3 and Wnt3a
- discuss significance of HS20 in cancer metastasis

### Mutation of HS20 to Remove an N-Glycosylation Site does not Alter Binding Affinity and Specificity

- modify HS20 to remove N-glycosylation site

### HS20 Inhibits HCC Tumor Growth In Vivo

- test HS20 antibody in HCC xenograft model

### The HN3 Human Antibody Inhibits HCC Tumor Growth In Vivo

- test HN3 antibody in HCC xenograft model

### Example 6

- generate HN3(VH)-PE38 immunotoxin
- express and purify HN3(VH)-PE38
- test cytotoxicity of HN3(VH)-PE38 against HCC cell lines
- evaluate tumor growth inhibition by HN3(VH)-PE38 in mice
- describe generation of HN3(VH)-PE38 immunotoxin
- describe cytotoxicity of HN3(VH)-PE38 against HCC cell lines
- describe tumor growth inhibition by HN3(VH)-PE38 in mice

